| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
MILPITAS, Calif.—Biopharmaceutical company AbVision Inc. announced May 1 that the company has developed a first-in-class COVID-19 vaccine (AVI-205) with an active targeting feature, powered by its patented ImmunoBuster-IITM Active Targeting Vaccine Platform.
 
This novel COVID-19 vaccine actively targets immune cells upon injection as compared to the passive diffusion mechanism of traditional vaccines, according to AbVision, generating strong SARS-CoV-2 S1-hACE2 neutralizing immune response in less than a week as compared to a two weeks similar response from traditional vaccines.
 
The company has now successfully completed preclinical studies and generated what is says are promising data. As a result, this novel COVID-19 vaccine candidate is now available for out-licensing and collaborations for downstream development and clinical studies, according to AbVision.
 
The company’s ImmunoBuster-II Active Targeting Vaccine Platform is, as described by AbVision, “a first-in-class potent immune activator with targeting feature, created on top of the innovation of the Company’s renowned ImmunoBuster-ITM technology. Vaccines powered by ImmunoBuster-IITM can elicit robust isotype switched IgG response in less than a week and maintain long-lasting IgG response for more than three weeks post vaccination.”
 
Reportedly, ImmunoBuster-IITM can work synergistically with essentially all commercially available vaccines to elicit faster and stronger neutralizing immunity than current vaccinations.

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue